Literature DB >> 29226617

Activation of glucagon-like peptide-1 receptors in the nucleus accumbens attenuates cocaine seeking in rats.

Nicole S Hernandez1,2, Bernadette O'Donovan3, Pavel I Ortinski3, Heath D Schmidt2,4.   

Abstract

Recent evidence indicates that activation of glucagon-like peptide-1 (GLP-1) receptors reduces cocaine-mediated behaviors and cocaine-evoked dopamine release in the nucleus accumbens (NAc). However, no studies have examined the role of NAc GLP-1 receptors in the reinstatement of cocaine-seeking behavior, an animal model of relapse. Here, we show that systemic infusion of a behaviorally relevant dose of the GLP-1 receptor agonist exendin-4 penetrated the brain and localized with neurons and astrocytes in the NAc. Administration of exendin-4 directly into the NAc core and shell subregions significantly attenuated cocaine priming-induced reinstatement of drug-seeking behavior. These effects were not due to deficits in operant responding or suppression of locomotor activity as intra-accumbal exendin-4 administration had no effect on sucrose-seeking behavior. To determine the effects of GLP-1 receptor activation on neuronal excitability, exendin-4 was bath applied to ex vivo NAc slices from cocaine-experienced and saline-experienced rats following extinction of cocaine-taking behavior. Exendin-4 increased the frequency of action potential firing of NAc core and shell medium spiny neurons in cocaine-experienced rats while no effect was observed in saline controls. In contrast, exendin-4 did not affect the frequency or amplitude of spontaneous excitatory postsynaptic currents or alter the paired-pulse ratios of evoked excitatory postsynaptic currents. These effects were not associated with altered expression of GLP-1 receptors in the NAc following cocaine self-administration. Taken together, these findings indicate that increased activation of GLP-1 receptors in the NAc during cocaine abstinence increases intrinsic, but not synaptic, excitability of medium spiny neurons and is sufficient to reduce cocaine-seeking behavior.
© 2017 Society for the Study of Addiction.

Entities:  

Keywords:  glucagon-like peptide-1; nucleus accumbens; relapse

Mesh:

Substances:

Year:  2017        PMID: 29226617      PMCID: PMC5995617          DOI: 10.1111/adb.12583

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  39 in total

Review 1.  Anatomy and pharmacology of cocaine priming-induced reinstatement of drug seeking.

Authors:  Heath D Schmidt; Sharon M Anderson; Katie R Famous; Vidhya Kumaresan; R Christopher Pierce
Journal:  Eur J Pharmacol       Date:  2005-12-05       Impact factor: 4.432

2.  Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats.

Authors:  Matthew R Hayes; Scott E Kanoski; Amber L Alhadeff; Harvey J Grill
Journal:  Obesity (Silver Spring)       Date:  2011-03-17       Impact factor: 5.002

Review 3.  Obesity and addiction: neurobiological overlaps.

Authors:  N D Volkow; G-J Wang; D Tomasi; R D Baler
Journal:  Obes Rev       Date:  2012-09-27       Impact factor: 9.213

4.  The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide.

Authors:  Scott E Kanoski; Laura E Rupprecht; Samantha M Fortin; Bart C De Jonghe; Matthew R Hayes
Journal:  Neuropharmacology       Date:  2011-12-28       Impact factor: 5.250

Review 5.  Metabolic hormones, dopamine circuits, and feeding.

Authors:  Nandakumar S Narayanan; Douglas J Guarnieri; Ralph J DiLeone
Journal:  Front Neuroendocrinol       Date:  2009-10-28       Impact factor: 8.606

6.  GLP-1 influences food and drug reward.

Authors:  Matthew R Hayes; Heath D Schmidt
Journal:  Curr Opin Behav Sci       Date:  2016-06

7.  Glucagon-like peptide-1 receptor activation in the nucleus accumbens core suppresses feeding by increasing glutamatergic AMPA/kainate signaling.

Authors:  Elizabeth G Mietlicki-Baase; Pavel I Ortinski; David J Reiner; Christopher G Sinon; James E McCutcheon; R Christopher Pierce; Mitchell F Roitman; Matthew R Hayes
Journal:  J Neurosci       Date:  2014-05-14       Impact factor: 6.167

8.  GLP-1 analog attenuates cocaine reward.

Authors:  D L Graham; K Erreger; A Galli; G D Stanwood
Journal:  Mol Psychiatry       Date:  2012-10-23       Impact factor: 15.992

9.  Real-time trafficking and signaling of the glucagon-like peptide-1 receptor.

Authors:  Sarah Noerklit Roed; Pernille Wismann; Christina Rye Underwood; Nikolaj Kulahin; Helle Iversen; Karen Arevad Cappelen; Lauge Schäffer; Janne Lehtonen; Jacob Hecksher-Soerensen; Anna Secher; Jesper Mosolff Mathiesen; Hans Bräuner-Osborne; Jennifer L Whistler; Sanne Moeller Knudsen; Maria Waldhoer
Journal:  Mol Cell Endocrinol       Date:  2013-11-22       Impact factor: 4.102

10.  GLP-1 acts on habenular avoidance circuits to control nicotine intake.

Authors:  Luis M Tuesta; Zuxin Chen; Alexander Duncan; Christie D Fowler; Masago Ishikawa; Brian R Lee; Xin-An Liu; Qun Lu; Michael Cameron; Matthew R Hayes; Theodore M Kamenecka; Matthew Pletcher; Paul J Kenny
Journal:  Nat Neurosci       Date:  2017-04-03       Impact factor: 24.884

View more
  21 in total

Review 1.  Central GLP-1 receptors: Novel molecular targets for cocaine use disorder.

Authors:  N S Hernandez; H D Schmidt
Journal:  Physiol Behav       Date:  2019-03-28

Review 2.  The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: A systematic review.

Authors:  Amanda Brunchmann; Morgane Thomsen; Anders Fink-Jensen
Journal:  Physiol Behav       Date:  2019-04-01

3.  Can anti-obesity drugs be repurposed to treat cocaine addiction?

Authors:  David J Reiner; Jennifer M Bossert
Journal:  Neuropsychopharmacology       Date:  2018-04-17       Impact factor: 7.853

Review 4.  GLP-1: Molecular mechanisms and outcomes of a complex signaling system.

Authors:  Nicholas K Smith; Troy A Hackett; Aurelio Galli; Charles R Flynn
Journal:  Neurochem Int       Date:  2019-04-17       Impact factor: 3.921

Review 5.  A novel approach to treating opioid use disorders: Dual agonists of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors.

Authors:  Riley Merkel; Amanda Moreno; Yafang Zhang; Rachel Herman; Jennifer Ben Nathan; Sana Zeb; Suditi Rahematpura; Kamryn Stecyk; Brandon T Milliken; Matthew R Hayes; Robert P Doyle; Heath D Schmidt
Journal:  Neurosci Biobehav Rev       Date:  2021-10-29       Impact factor: 8.989

6.  Binge-like palatable food intake in rats reduces preproglucagon in the nucleus tractus solitarius.

Authors:  Ashmita Mukherjee; Avery Hum; Tyler J Gustafson; Elizabeth G Mietlicki-Baase
Journal:  Physiol Behav       Date:  2020-02-13

7.  Association between GLP-1 receptor gene polymorphisms with reward learning, anhedonia and depression diagnosis.

Authors:  Hale Yapici-Eser; Vivek Appadurai; Candan Yasemin Eren; Dilek Yazici; Chia-Yen Chen; Dost Öngür; Diego A Pizzagalli; Thomas Werge; Mei-Hua Hall
Journal:  Acta Neuropsychiatr       Date:  2020-03-26       Impact factor: 3.403

8.  Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder.

Authors:  Gustavo A Angarita; David Matuskey; Brian Pittman; Jessica L Costeines; Marc N Potenza; Ania M Jastreboff; Heath D Schmidt; Robert T Malison
Journal:  Drug Alcohol Depend       Date:  2021-02-15       Impact factor: 4.492

9.  Glucagon-like peptide-1 receptor agonist, exendin-4, reduces reinstatement of heroin-seeking behavior in rats.

Authors:  Joaquin E Douton; Corinne Augusto; Brooke Stoltzfus; Nurgul Carkaci-Salli; Kent E Vrana; Patricia S Grigson
Journal:  Behav Pharmacol       Date:  2021-06-01       Impact factor: 2.293

10.  Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent.

Authors:  Mathias E Jensen; Aurelio Galli; Morgane Thomsen; Kathrine L Jensen; Gerda K Thomsen; Mette K Klausen; Tina Vilsbøll; Mikkel B Christensen; Jens J Holst; Anthony Owens; Sabrina Robertson; Lynette Daws; Daniele Zanella; Ulrik Gether; Gitte M Knudsen; Anders Fink-Jensen
Journal:  Neurochem Int       Date:  2020-05-25       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.